StemCell Therapy

Pancreatic cancer is an insidious disease itis often diagnosedat an advanced stage, with about 90% of patients dying within five years of diagnosis.New projections suggest pancreatic cancer will be the second leading cause of cancer mortality by 2025.

This World Pancreatic Cancer Day, we are celebrating some of the many UNSWresearchers who are dedicated to changing those statistics. Cancers with poor outcomes like pancreatic cancer are a key focus area in UNSW Medicine's cancer theme.

Associate Professor Phillips is the Head of the Pancreatic Cancer Translational Research Group and Deputy Director of the Adult Cancer Program at the Lowy Cancer Research Centre at UNSW Medicine.

This year, A/Prof Phillips was a key driver in establishing the Pancreatic Cancer Research Hub, which aims to double the survival of patients with pancreatic cancer by 2030.

She says World Pancreatic Cancer Day is a powerful advocacy event to increase community and government awareness of pancreatic cancer.

It is also a time to reflect on the progress we have made in understanding this terrible disease and focus on the next steps to overcome current clinical challenges to ensure our research efforts bridge the gap and, as in other cancers, improve the outcomes for our patients with pancreatic cancer.

I know that we are on the brink of overturning the unacceptable statistics. Uniting researchers with the community who, unlike in other cancers, dont often get to be a strong voice advocating for themselves and Government will ensure Australian researchers continue to make positive change for pancreatic cancer patients globally.

A/Prof Phillips group has developed a novel cutting-edge way to keep pieces of human pancreatic tumours alive in the laboratory for two weeks after surgical resection.

Our capacity to grow human tumour tissue in the laboratory provides a valuable new clinical tool to test how a patients tumour responds to different chemotherapies and has the potential to immediately inform patient treatment options. Our unique tumour model is superior to other models because it is human in origin and it contains the complex tumour environment present in patients.

In 2016 A/Prof Phillips had a major breakthrough, successfully developing a novel nanomedicine a tiny drug delivery vehicle consisting of a state-of-the-art nanoparticle that can package gene therapy to inhibit any tumour-promoting gene in pancreatic cancer.

With the generous support from the Brian O'Neill Pancreatic Cancer Fundraising Dinner held last night the team will be able to perform essential preclinical studies to test the therapeutic potential of their nano-gene therapy in combination with a clinically approved drug. They also plan on using their expertise to improve the bioavailability of the clinically approved drugs using a nanomedicine approach.

Professor Minoti Apte was the first in the world to isolate and characterise pancreatic stellate cells, a cell type that is now known to play a major role in the progression of both chronic pancreatitis and pancreatic cancer. Coming up with ways to target these cells to prevent them from doing harm is now a major focus of her teams research.

The group has now shown that interrupting the cross-talk between cancer cells and surrounding cells in the microenvironment by targeting a certain signalling pathway reduces tumour growth and eliminates metastasis in early as well as advanced pre-clinical models of pancreatic cancer.

We have also shown that targeting this pathway reduces the risk of recurrence and progression after surgical resection of pancreatic cancer in a mouse model, and are currently working on possible pathways to take our laboratory findings to the clinic, Professor Apte says.

To me, World Pancreatic Cancer Day is a great opportunity to raise awareness in the community about this deadly cancer, but it is also a day to admire the courage and resilience of patients and their carers. These are the people that spur us researchers on to continue working hard to develop new therapeutic approaches to improve outcomes.

Last year, Professor Apte received the Gastroenterological Society of Australia (GESA) Distinguished Researcher Prize 2018. In 2014 she was awarded the Medal of the Order of Australia (OAM), after being named the NSW Woman of the Year in 2015. She was also the 2016 recipient of the Professor Rob Sutherland AO Make a Difference Award at the NSW Premiers Awards for Outstanding Cancer Research an award that recognises highly successful research that is actively changing cancer treatment and improving patient survival.

Dr Angelica Merlot, who is based at the Childrens Cancer Institute, focuses her research on developing new anti-cancer drugs that target drug resistance and suppress cancer spread.

This year, the cancer researcher has won the 2019 NSW Young Woman of the Year award for her achievements and research into treatments for pancreatic and brain cancer. She also won a 2019 Young Tall Poppy Science Award and the 2019 NSW Early Career Researcher of the Year (Biological Sciences) at the NSW Premiers Prizes for Science & Engineering.

Dr Merlot says today is an important day to raise awareness about one of the world's toughest cancers.

This is crucial as it broadens community knowledge, inspires action and supports further research funding for this cancer. It's also a time to remember those whom we have lost and those currently fighting this disease, she says.

Although we've seen a small improvement in the current survival rate, a lot of progress is still required. Further translational research means that there is a greater likelihood that the survival rates can be increased and the journey and treatment of those affected by the cancer can be improved.

Dr Merlot became focused on cancer research as an undergraduate. Her interest in aggressive cancers, such as pancreatic and brain cancer, was motivated by lack of improvement in survival rates over the past decades, largely due to late diagnosis, a lack of screening programs, low awareness of symptoms and a lack of treatment options.

After moving to UNSW Medicine as a Scientia Fellow in 2018, Dr Merlot focused on understanding the mechanisms by which cancer cells grow and adapt to their environment, why drugs become less effective and the development of nanoparticles to improve drug delivery.

Dr Merlots current projects are investigating part of a human cell called the endoplasmic reticulum (ER). The ER is a type of organelle, or subunit within a cell, that has been shown to help cancers grow, spread and develop drug resistance.

Dr Ying Zhu will lead a team of researchers from UNSW to discover much needed early detection methods for pancreatic cancer patients: the UNSW Medicine researcher today received $100,000 grant from the Avner Pancreatic Cancer Foundation. A/Prof Phillips is a co-investigator on this grant.

As current approaches to this research are time and labour intensive, the team will develop an integrated and small device based on nanotechnology for rapid and sensitive exosome analysis. The team will define a set of biomarkers that can differentiate between cancer and non-cancer subjects from cells and plasma carrying early signs of human pancreatic cancer. This novel technology will also be applicable for doctors monitoring the development and customising the treatment of a patients tumour.

Pancreatic cancer is difficult to diagnose in the early stages. Early tumour cant be observed during routine physical exams as the pancreas is deep inside the body. Most patients are diagnosed when the cancer has become very large or has spread to other organs. A method to detect pancreatic cancer early on is urgently needed, Dr Zhu said.

My project team aims to develop a blood test to detect pancreatic cancer in the early stages. The team will target exosomes, which are nanosized fragments released by cancer cells. Exosomes are important for communicating messages and transporting materials between cells. Exosomes have been identified as more accurate and promising biomarkers, or biological clues for pancreatic cancer diagnosis, Dr Zhu continued.

We are pleased to award funding to this innovative project, said Michelle Stewart, CEO of the Avner Pancreatic Cancer Foundation. We are encouraged by the high calibre of the research and believe that investment into projects like these will help us to increase survival for people diagnosed with pancreatic cancer.

Read the original post:
World Pancreatic Cancer Day: increasing awareness and inspiring action - UNSW Newsroom

A new market assessment report on the Nanomedicine market provides a comprehensive overview of the Nanomedicine industry for the forecast period 2019 2026. The analytical study is proposed to provide immense clarity on the market size, share and growth rate across different regions. The profound knowledge and extensive examination of the trends from the yesteryear and future aims at offering the stakeholders, product owners, and marketing personnel a competitive edge over others operating in the Agricultural Tires market for the forecast period, 2019 2026.

The study will also feature the key companies operating in the industry, their product/business portfolio, market share, financial status, regional share, segment revenue, SWOT analysis, key strategies including mergers & acquisitions, product developments, joint ventures & partnerships an expansions among others, and their latest news as well. The study will also provide a list of emerging players in the Nanomedicine market.

In this report, theglobal Nanomedicine marketis valued atUSD xx million in 2019and is expected to reachUSD xx millionby the end of2026, growing at aCAGR of xx.x%between 2019 and 2026.

Download FREE Sample Brochure (Customized Sample PDF File delivered as per your specific requirement) @https://www.reportsanddata.com/sample-enquiry-form/1048

The major manufacturers covered in this report:Arrowhead Pharmaceuticals Inc. AMAG Pharmaceuticals, Bio-Gate AG, Celgene Corporation and Johnson & Johnson. Johnson & Johnson

The study is a professional probe into the revenue generated and capacity estimates for the Nanomedicine market for the forecast period 2019 2026 empower the business owners to maintain a competitive edge over their rivals.

The research further examines and provides data on the market by type, application and geography interspersed with illustrations and other graphical representations. The market analysis not only determines the attractiveness of the industry but also the evolving challenges and opportunities and their association with the weaknesses and strengths of prominent market leaders.

Other factors taken into consideration when studying the industry include profitability, manufacturing capability, distribution channels and industry cost structure and major success factors.

The industry experts have left no stone unturned to identify the major factors influencing the development rate of the Nanomedicine industry including various opportunities and gaps. A thorough analysis of the micro markets with regards to the growth trends in each category makes the overall study interesting. When studying the micro markets the researchers also dig deep into their future prospect and contribution to the Nanomedicine industry.

Product Outlook (Revenue, USD Billion, 2018-2026)

Therapeutics

Regenerative Medicine

In-vitro diagnostics

In-vivo diagnostic

Vaccines

Drug Delivery System Outlook (Revenue, USD Billion, 2018-2026)

Nanobots

Nanoghosts

Nanoclusters

Nanobubbles

Exosomes

Injectable Nanoparticle Generator

Dendrimers

Liposomes

Carbon nanotube

Graphene

Others

Application Outlook (Revenue, USD Million, 2015-2026)

Oncology

Infectious diseases

Cardiology

Orthopedics

Others

!!! Limited Time DISCOUNT Available!!! Get Your Copy at Discounted [emailprotected]https://www.reportsanddata.com/discount-enquiry-form/1048

Key Research:

The main sources are industry experts from the global Nanomedicine industry, including management organizations, processing organizations, and analytical services providers that address the value chain of industry organizations. We interviewed all major sources to collect and certify qualitative and quantitative information and to determine future prospects. Through interviews in the industry experts industry, such as CEO, vice president, marketing director, technology and innovation director, founder and key executives of key core companies.

Secondary Research:

Secondary research studies critical information about the industrial value chain, core pool of people, and applications. We also helped market segmentation based on the industrys lowest level of industry, geographical markets and key developments in market and technology-driven core development.

Geographically, this report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering:

United States

Europe

China

Japan

Southeast Asia

India

Incorporated with Info-graphics, charts, 75 tables and 105 figures, this 243-page research report NanomedicineMarket Size, Type Analysis, Application Analysis, End-Use Industry Analysis, Regional Outlook, Competitive Strategies And Forecasts, 2019 2026 is based on a complete research of the entire Global market and covering all its sub-segments through comprehensively thorough classifications. Insightful analysis and assessment are created from superior primary and secondary information sources with data and information derived from industry specialists across the value chain. The report provides historical market data for 2014-2018, base year estimates for 2018, and forecasts from 2019 to 2026.

Table of Contents:

Report Overview:It includes the objectives and scope of the study and gives highlights of key market segments and players covered. It also includes years considered for the research study.

Executive Summary:It covers industry trends with high focus on market use cases and top market trends, market size by regions, and global market size. It also covers market share and growth rate by regions.

Key Players:Here, the report concentrates on mergers and acquisitions, expansions, analysis of key players, establishment date of companies, and areas served, manufacturing base, and revenue of key players.

Breakdown by Product and Application:This section provides details about market size by product and application.

Regional Analysis:All of the regions and countries analyzed in the report are studied on the basis of market size by product and application, key players, and market forecast.

Profiles of International Players:Here, players are evaluated on the basis of their gross margin, price, sales, revenue, business, products, and other company details.

Market Dynamics:It includes supply chain analysis, analysis of regional marketing, challenges, opportunities, and drivers analyzed in the report.

Appendix:It includes details about research and methodology approach, research methodology, data sources, authors of the study, and a disclaimer.

For further information on this analysis, please visit @https://www.reportsanddata.com/report-detail/nanomedicine-market

Why Choose Reports and Data?

Request customized copy of Nanomedicine report

We are grateful to you for reading our report. If you wish to find more details of the report or want a customization, contact us. You can get a detailed information of the entire research here. If you have any special requirements, please let us know and we will offer you the report as you want.

Have Any Query? Ask Our Expert @https://www.reportsanddata.com/make-enquiry-form/1048

Read more here:
Nanomedicine Market Segmented by Applications and Geography Trends, Growth and Forecasts 2026 - The Bay State Herald

DUBLIN--(BUSINESS WIRE)--The "Global Next-Generation Sequencing (NGS) Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

The Global Next-Generation Sequencing (NGS) market is expected to reach $25.09 billion by 2026 growing at a CAGR of 20.6% from 2018 to 2026.

Low cost, high accuracy & speed, and exact outcomes even from low sample input are the fundamental advantages it offers over Sanger's sequencing technique. It is utilized to execute different applications for example, biomarker discovery, oncology studies, personalized medicine, agricultural & animal research, and others. It has streamlined nucleotide analysis and has generally replaced conventional tools of genomics, particularly microarray efficiently. Consequently, these aforementioned factors help in expanding the market share.

Factors such as rise in technological advancements and increase in partnerships & collaborations are driving the market growth. Though, lack of skilled professionals, and ethical & legal limitations are projected to inhibit the growth of the market. Moreover, cloud computing as a potential data management service and lucrative opportunities in emerging markets may provide ample opportunities for the market growth.

By end user, academic institutes & research centers segment acquired significant growth in the market owing to the increasing number of collaborations between the market players and academic & research institutions and on the account of wide usage of these methodologies in research and Ph.D. projects, on-site bioinformatics courses, and workshops across regions, and the development of cost-efficient products and services for researchers is leading to the market growth.

The key vendors mentioned are 10x Genomics, Agilent Technologies Inc, Beckman Coulter (A Subsidiary of Danaher), Becton, Dickinson and Company, BGI, Eurofins Scientific, F. Hoffmann-La Roche AG, Genewiz, Illumina Inc, Macrogen Inc, Oxford Nanopore Technologies Ltd, Pacific Biosciences of California Inc, Perkinelmer Inc, Qiagen N.V. and Thermo Fisher Scientific Inc.

Key Questions Answered in this Report

Key Topics Covered

1 Market Synopsis

2 Research Outline

3 Market Dynamics

3.1 Drivers

3.2 Restraints

4 Market Environment

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Next-Generation Sequencing (NGS) Market, By Disease

5.1 Introduction

5.2 Rare Disease Diagnostics

5.3 Cardiovascular

5.4 Other Diseases

6 Global Next-Generation Sequencing (NGS) Market, By Service

6.1 Introduction

6.2 Sequencing Services

6.3 Animal & Plant Sequencing

6.4 Gene Regulation Services

6.5 Human Genome Sequencing Services

6.6 Microbial Genome - based Sequencing Services

6.7 Single Cell Sequencing Services

7 Global Next-Generation Sequencing (NGS) Market, By Type of Sequencing

7.1 Introduction

7.2 CHIP Sequencing

7.3 De Novo Sequencing

7.4 Illumina Sequencing

7.5 Methyl Sequencing

7.6 Pre-Sequencing

7.7 RNA Sequencing

7.8 Targeted Sequencing & Resequencing

7.9 Whole Exome Sequencing

7.10 Whole Genome Sequencing

8 Global Next-Generation Sequencing (NGS) Market, By Informatics

8.1 Introduction

8.2 Primary and Secondary Data Analysis Tools

8.3 NGS Informatics Services

8.4 Computing

8.5 Storage

8.6 LIMS (Laboratory Information Management System)

8.7 Biological Interpretation and Reporting Tools

9 Global Next-Generation Sequencing (NGS) Market, By Product

9.1 Introduction

9.2 Reagents & Consumables

9.3 Instruments

9.4 Platforms

9.5 Software

9.6 Services

10 Global Next-Generation Sequencing (NGS) Market, By Technology

10.1 Introduction

10.2 454 Technology

10.3 DNA Nano Ball Sequencing

10.4 Ion Semiconductor Sequencing

10.5 Ion Torrent Sequencing

10.6 Ion Semiconductor Sequencing

10.7 Massively Parallel Signature Sequencing (MPSS)

10.8 Nanopore Sequencing

10.9 Pyrosequencing

10.10 Reversible Terminator Sequencing

10.11 Sequencing by Ligation (SBL)

10.12 Sequencing By Synthesis

10.13 Sequencing by Synthesis (SBS)

10.14 Single Molecule Real Time (SMRT) Sequencing

10.15 Single-Molecule Real-Time Sequencing

10.16 Supported Oligonucleotide Ligation and Detection (SOLiD)

11 Global Next-Generation Sequencing (NGS) Market, By Application

11.1 Introduction

11.2 Agrigenomics & Forensics

11.3 Biomarker Discovery and Cancer

11.4 Cardiovascular

11.5 Clinical Investigation

11.6 Consumer Genomics

11.7 Drug Discovery

11.8 Emerging Application

11.9 Forensics

11.20 Genetic Analysis

11.21 Hereditary Disease Detection

11.22 HLA Typing/Immune System Monitoring

11.23 Human Leukocyte Antigen (HLA) Testing

11.24 Infectious Disease Diagnostics

11.25 Life Science

11.26 Metagenomics, Epidemiology & Drug Development

11.27 Oncology

11.28 Pharmaceuticals

11.29 Precision Medicine

11.30 Reproductive Health

12 Global Next-Generation Sequencing (NGS) Market, By End User

12.1 Introduction

12.2 Academic Institutes & Research Centers

12.3 Agriculture and Animal Research

Read more:
Global Next-Generation Sequencing (NGS) Market Report 2019 - World Market Projected to Surpass $25 Billion by 2026, Rising at a CAGR of 20.6% -...

Editors note: This is part of a series about bankruptcy in the biopharma industry. Click here to see a running list of 2019 biopharma bankruptcies, and click here to see 31 biopharmas at high risk of bankruptcy for 2020.

Six years ago, Bind Therapeutics was flying high, with little idea how hard it would soon crash.

Headed into a public stock offering in 2013, the biotech, founded by top MIT and Harvard researchers, generated buzz with its lofty scientific ambitions. Company executives believed its nanomedicine platform, while only through Phase 1 tests, represented the next advance in cancer therapies.

Those dreams came undone within three years. As its experimental therapies struggled in clinical testing, Bind was punished by the market, and debt repayments forced the company into bankruptcy in 2016.

Bind may be a cautionary story in todays life sciences ecosystem, one that features biotechs going public at earlier stages and with heightened ambitions.

While bankruptcy is a rare outcome for biopharmas, 2019 has bucked that trend with an uptick in Chapter 11 filings. Eleven companies have declared bankruptcy so far this year, compared to an average of four per year during the past decade, according to a review of data tracked by the firm BankruptcyData.

That increase may forewarn of more companies falling to zero, industry experts said in interviews with BioPharma Dive, especially at a time of rising legal and political headwinds for the sector. After a decade of booming growth, the ballooning ranks of newly public biotechs may struggle to withstand market pressures.

I think theres a turning point now, said Andrew Hirsch, the former CEO of Bind, in an interview. I think its not sustainable.

Hirsch highlighted the rising prominence of early-stage platform companies, like Bind, going public in greater numbers and at larger valuations. That can bring steeper downside, he warned.

Things arent always going to work the first time, thats just the rule in this industry. A lot of times, companies are valued for perfection, said Hirsch, now Agios Pharmaceuticals chief financial officer.

If they are lucky and it works, thats great. But if you have a setback because youre doing novel things, the public markets can be a cruel place to be.

Biotech vastly outperformed the broader stock market over the past decade, and a steady inflow of capital supported more companies going public at rich valuations.

But those tides have turned. A leading biotech index has fallen more than 15% since peaking in the summer of last year, while the S&P 500 has ticked up nearly 13% in the same timeframe. The capital required for funding biopharmas ambitions is leaving too, with one Wall Street firm calculating $8.7 billion in net capital outflows this year rivaling a stretch in late 2015 and early 2016.

After years of outperformance, biotech has lagged the market for the past year

Price per share of a leading biotech index (XBI) and the S&P 500 (SPX) from January 2018 to October 2019 (indexed)

The base value of the index is trading value on Jan. 2, 2018.

Nami Sumida/BioPharma Dive

Investor anxiety is rising at a time when more companies are fighting for funding than in past decades. Evercore ISI analyst Josh Schimmer said this year hes noticed a marked shift in investor attitudes.

When they stumble, the markets are more unforgiving than ever, Schimmer said in an interview. They arent given second chances the way they used to be given. That may be a factor that does lead to a higher rate of bankruptcies.

And small biotechs arent the only ones facing elevated bankruptcy risk. The weight of thousands of lawsuits related to opioid marketing has already taken down Purdue Pharma and Insys Therapeutics. Several others, like Teva Pharmaceutical, Mallinckrodt and Amneal, are at risk of joining them.

The legal uncertainty has made these companies perceived as uninvestable, SVB Leerink analyst Ami Fadia said in an interview. Additionally, many of these pharmas are highly leveraged and face issues in generating cash going forward, she added.

Its pretty obvious that some of these companies are at high risk of bankruptcy, said Fadia, who covers several of these drugmakers including Mallinckrodt and Amneal.

To be sure, the effect of opioid liabilities is constrained to a comparatively small set of companies. But heading into an election year with drug pricing as a top issue, worries about capital fleeing the industry and a legal crackdown on opioid makers could be exacerbated by political threats as well.

Industry lobbyists have blasted HR3, the leading Democratic drug pricing proposal, saying it would trigger a nuclear winter by eroding the upside of biopharmas high-risk, high-reward investment premise.

If HR3 becomes law, it is lights out for a lot of very small biotech companies that are pre-revenue and depend on attracting capital, PhRMA CEO Stephen Ubl said at a recent media briefing.

Industry-specific concerns, of course, come against the backdrop of fears of a broader economic slowdown. Financial analysts have flagged recession signals in the U.S., which, if materialized, would further squeeze the industry.

It may be coming, in which capital itself is scarcer for companies, said Bob Eisenbach, a lawyer at Cooley specializing in bankruptcies. And when that happens, it puts pressure even on good companies.

Biopharmas are structured to avoid bankruptcies. Pre-revenue companies typically carry little debt and have little to restructure through a bankruptcy court if their pipeline fizzles.

Privately held biotechs that suffer clinical failures can also avoid bankruptcy by having their financial backers buy them out, saving face for those venture capitalists.

It just disappears into this great maw of the biotech universe, said Kevin Kinsella, a venture capitalist and founder of Avalon Ventures, referring to distressed biotechs in an interview.

Having launched more than 100 biopharmas, including prominent names like Vertex, Neurocrine and Onyx, Kinsella said hes been lucky enough to avoid getting entangled in any bankruptcies.

Someone absolutely failing, shutting the doors and turning off the lights, you dont really see that a lot in our industry, he said.

Drug companies, both young and old, derive value from ideas and hope more than tangible assets or resources. Just last year, early-stage platform companies like Moderna Therapeutics and Rubius Therapeutics went public with multi-billion dollar valuations despite lacking profits and significant clinical data.

But investor attitudes appear to have shifted. Rubius stock, for instance, has dropped more than 70% since its IPO. While up this month, shares in Moderna are 30% off their 52-week high in May.

Speaking generally about platform companies, Binds former CEO said market sentiment has turned.

Investors have lost their appetite for companies going public with preclinical data, Hirsch said.

Youre probably going to see more of these situations going forward, where a company is preclinical, went public and is left on their own and has to raise additional money from the public markets and they flounder.

Yet even floundering biotechs can persist for years, even decades. Long-standing industry veterans like Xoma, Novavax and Geron have survived in as-yet fruitless searches for their first drugs, suffering clinical failures along the way. Despite accumulated deficits exceeding $1 billion, these companies can find the necessary capital to keep chugging along.

Theres always someone else whos willing to bet the next discovery is around the corner, or the next asset, or if we get this clinical trial enrolled and finished, all will be good, Kinsella said. Theres always hope.

Besides selling hope, biopharmas, like all businesses, have practical options to stave off bankruptcy. Restructuring and raising cash are the main focuses, turnaround experts said.

Corporate restructurings typically shrink the business, either by laying off employees, selling assets or killing off R&D projects. Raising capital can include licensing rights to experimental therapies, taking on debt or tapping the public markets for secondary stock offerings.

If those options are exhausted, M&A can be another way out for shareholders. Firms like Deerfield Management, Hercules Capital and Highbridge Capital Management often aid distressed biotechs in such endeavours.

Deerfield, for instance, reached deals to finance R&D costs for Dynavax and helped fund Melinta Therapeutics acquisition of an infectious disease business.

A last resort can be merging with another struggling biotech, or becoming the shell in a reverse merger for another company seeking an easy path to a public listing.

Both happened in just the past few weeks. Foamix Pharmaceuticals and Menlo Therapeutics merged into one dermatology company, while NewLink Genetics was the shell through which Lumos Pharma joined public markets.

These strategies act as moats that insulate a high-risk industry from bankruptcy. In recent years, they have worked tremendously well. Among the 333 biopharmas that have gone public since 2012, just 3% filed for bankruptcy while 6% became reverse merger shells and 10% exited via M&A, according to data tracked by Evercore ISI.

But with 2019 looking shaky for biopharma, some have begun to wonder how markets will respond.

The last few years have featured record levels of capital raising, according to the investment bank Jefferies, which tallied 100 initial public offerings and 270 follow-on raises in 2018 and 2019 that drummed up tens of billions in cash.

At the same time, the number of public small and mid-sized biotechs has doubled in the past decade. There arent just more of these smaller firms; they also are worth more and consume more capital on average. From 2010 to present, these companies have seen their typical market values double, R&D budgets triple and cash burn rates quadruple, Jefferies found.

The annual burn rate for these biotechs, which includes market values from $200 million to $5 billion, has increased from $20 million to $80 million. Jefferies analyst Michael Yee credited that to free-flowing capital, more platform companies and an arms race in oncology.

Biotechs impressive market performance has made that possible. A leading biotech index, for instance, outperformed the S&P 500 by 30% since the market bottomed out in March 2009.

But of late, biotech has struggled, creating a tougher environment to raise cash.

The question is whether this is sustainable if market and macro conditions get tougher and political uncertainty gets more obvious, forcing companies to tighten their belts to ride out 2020, Yee wrote.

2019 has brought an uptick in industry bankruptcy filings

Credit: Data from Bankruptcy Data

Conditions have clearly worsened by some metrics, such as the amount of money invested in healthcare- or biotech-dedicated funds. Data tracked by a Piper Jaffray found $8.7 billion in investment has left such funds in 2019. Ten of the past 12 weeks have registered net capital outflows, a streak a Piper Jaffray analyst called seemingly the new normal.

Billions of dollars flowed out of biotech in 2015 and 2016, too, at a time when many biotech shares were falling and the prospect of a Hillary Clinton presidency had raised investor fears on drug pricing.

Biotech weathered that storm, with few companies entering bankruptcy, and has grown since. Going forward, a critical question will be gauging whether the sector is on a new trajectory or if it will emerge from this period relatively unscathed.

Getting investor attention is harder than ever to begin with, said Evercores Schimmer. For a company that has faltered, even if they are doing the right thing, its a struggle.

See the rest here:
Bankrupt biopharmas are rare. 2019 has some worried that's changing. - BioPharma Dive

PALO ALTO, Calif.--(BUSINESS WIRE)--NTT Research, Inc., a division of NTT (TYO:9432), today announced that its Medical and Health Informatics (MEI) Lab has entered a joint research agreement with the Technical University of Munich (TUM) to work on three-dimensionally transformable and implantable electrodes. Dr. Hitonobu Tomoike (M.D., Ph.D.), a renowned scientist and medical researcher, directs the MEI Lab, which will be collaborating with Dr. Bernhard Wolfrum, Professor of Neuroelectronics at TUM in the Department of Electrical and Computer Engineering and the Munich School of BioEngineering (MSB). The scope of work for this multi-year project includes screening and optimizing functional materials, assembling 3D structures, and evaluating their biocompatibility.

Charged with discovering technologies that can revolutionize patient care, the NTT Research MEI Lab is focusing on the transformation and miniaturization of medical device components. This joint research will address the tendency of conventional electronics to work against and at a relative distance from, rather than with and alongside their targeted organ or tissue. The flexible micro- or nano-scale electrodes envisioned as an outcome of this project are expected to minimize the negative impact that rigid and planar electrode materials have on soft and curvilinear biological samples.

In order to acquire in vivo biological signals stably, with a high accuracy for a long period of time, a flexible electrode with high biocompatibility is required, said Dr. Tomoike. To achieve this, we will use nano and micro-scale conductive polymer thin films that are friendly to living bodies and consider the use of in vivo implant electrodes, as well as the control of structural changes of the functional electrodes in the body.

The two principal researchers bring considerable expertise to this project. Dr. Tomoike, former Director of the Sakakibara Heart Institute, Director Emeritus at the National Cerebral and Cardiovascular Center in Japan, and former Professor of Cardiology at Yamagata University, is known for his work in precision medicine involving bio-sensors and analytics. Dr. Wolfrums research focuses on neuro- and bioelectronics. He has developed electrochemical sensor arrays and interfaces to cellular networks and employed microfabrication techniques, advanced printing technologies, and microfluidic cell culture methods with the goal of establishing neuroelectronic hybrids and systems for on-chip neuroscience and bioelectronic medicine.

The Technical University of Munich has strengths in neuron growth control and electrophysiological measurement and has recently accumulated know-how and knowledge of printing technology for bioelectronics, said Dr. Tomoike, who is also a Fellow of the American College of Cardiology and of the American Heart Association. We are aiming for breakthroughs in fundamental material science and unprecedented technologies for diagnostic, therapeutic and surgical functions.

Along with pursuing ambitious research targets, this agreement also advances NTT Researchs goal of engaging with partners around the world. As part of this project, NTT Research MEI Lab will send two of its researchers to Munich. The MEI Lab also plans to open an office in Germany. The research will officially launch in Q1 2020; the first phase of the project may take as long as three years.

We are very pleased to have entered this long-term joint research agreement with the MEI Lab of NTT Research and believe our combined strengths will lead to promising advances in a critically important field of bioengineering, said Dr. Wolfrum, who conducted postdoctoral research in nanoscience at Delft University, has led a research group at the Peter Grnberg Institute in Jlich, lectured at Aachen University, and conducted research as a visiting associate professor at Tohoku University in Sendai.

Throughout this interdisciplinary research project, the two organizations are expected to leverage their respective strengths. The Technical University of Munich, which is a member of the TU9 alliance of nine leading German institutes of technology, will be involved through its Neuroelectronics Group (NEL), Munich School of BioEngineering, in the investigation, characterization, and micro/nanofabrication of materials. For its part, the MEI Lab will design experiments and research targets and conduct data analysis based on IoT and AI technologies. Each party will assume roles in evaluating the biocompatibility of fabricated devices.

One notable aspect of this project, according to Dr. Tomoike, is its focus on the physics of soft nanomaterials, the self-assembly of which allows not only for precise control of 3D structures but also reversible transformation of electrodes that interface and function with cells and tissues. Possible applications involve sensing and stimulation electrodes for the brain and heart, brain-machine interfaces, multi-array electrodes for neuronal analysis, and new approaches to vasodilation.

About NTT Research

NTT Research opened its Palo Alto offices in July 2019 as a new Silicon Valley startup to conduct basic research and advance technologies that promote positive change for humankind. Currently, three labs are housed at NTT Research: the Physics and Information Science (PHI) Lab, the Cryptography and Information Security (CIS) Lab, and the Medical and Health Informatics (MEI) Lab. The organization aims to upgrade reality in three areas: 1) quantum information, neuro-science and photonics; 2) cryptographic and information security; and 3) medical and health informatics. NTT Research is part of NTT, a global technology and business solutions provider with an annual R&D budget of $3.6 billion.

NTT and the NTT logo are registered trademarks or trademarks of NIPPON TELEGRAPH AND TELEPHONE CORPORATION and/or its affiliates. All other referenced product names are trademarks of their respective owners. 2019 NIPPON TELEGRAPH AND TELEPHONE CORPORATION

More:
NTT Research and Technical University of Munich (TUM) Enter Joint Research Agreement to Collaborate on Technologies to Affect the Future of Patient...

Image Credit: phive/Shutterstock.com

Nanoform, a Finnish nanotechnology and drug particle engineering company, has won the prestigious Excellence in Pharma Award for Formulation at the 16th CPhI Pharma Awards which took place in Germany this November.

The prize sees world-renowned innovative companies competing against one another. This year Nanoforms ingenious medicine enabling nanotechnology, in the form of its CESS nanonization technology, won the highly contested award.

Who are Nanoform?

International pharmaceutical and biotechnology companies are well aware of the work that Nanoform dedicates itself to. Nanoform partners with businesses with the aim to boost their molecules formulation performance as well as to reduce clinical attrition. Nanoform is committed to working with international companies to provide them with cutting-edge, innovative solutions for the development and delivery of drugs.

The technology that won it the esteemed prize at the CPhI Pharma Awards was its multi-patented nanonization process which was designed with the capability of substantially improving dissolution rates and bioavailability, having the impact of doubling the number of drug compounds reaching clinical trials. In addition, the innovation has been shown to add value to the drug delivery spaces of pulmonary, transdermal, ocular and blood-brain barrier.

For this innovative new process, Nanoform surpassed the efforts of other respected companies such as Cambrex, Lonza Capsugel, and Glatt Pharmaceutical Services, who had also entered in the same category.

The Innovation

The new CESS, short for Controlled Expansion of Supercritical Solutions, nanonization technology has multiple patents for its unique design. It creates designed-for-purpose, nano-sized active pharmaceutical ingredient (API) particles, using a process that can control the particles shape, increasing uniformity. The system also has the ability to produce nanoparticles as small as 10 nm.

The method works by controlling the solubility of an API in supercritical carbon dioxide (scCO2) through a bottom-up method of recrystallization. Previous alternatives had been limited, and the CESS system surpasses those due to its utilization of controlled mass transfer, pressure reduction and flow. Another benefit of the system is that it is green, its process is free from using excipients and organic solvents.

Through Nanoforms innovation, novel opportunities are opening up to the field of drug research and development.

The Significance of the CESS System

Nanomaterials have unique properties that differ from their bulk material counterparts. These different properties have made them of special interest to a number of scientific fields, which has boosted exploration into nanoparticles over recent years. It has been found that these unique properties have potential applications in the areas of nanomedicine, therapeutics, medical devices and more. They have been identified as vectors for medical imaging, biological diagnostics and therapeutics.

What has been achieved by Nanoform is that another avenue of potential use has been opened up for nanoparticles. Nanoform has developed a reliable system that allows the benefits of nanoparticles to be harnessed in drug research and development. The unique properties of nanoparticles will be able to be put to use in developing new therapeutic treatments, which could induce a significant shift in the pharmaceutical sector.

It is generally accepted that advancements in the use of nanoparticles in this area would significantly influence the advancement of human therapeutics. Now pharmaceutical companies have access to a system that allows them to tailor-make nanoparticles, the innovation of new therapies that previously would not have been possible could be on the horizon.

Read more from the original source:
Nanoform Wins Award for Drug Development and Delivery - AZoNano

A new type of micromotor has been developed. Directed by magnets and powered by ultrasound, these micromotors are capable of traveling across microscopic particles and cells in very crowded areas without causing any damage.

These microswimmers provide a new way to manipulate single particles with precise control and in three dimensions, without having to do special sample preparation, labeling, surface modification, said Joseph Wang, a professor of nanoengineering at University of California San Diego (USCD), in a UCSD press release.

Wang, Thomas Mallouk, a professor of chemistry at the University of Pennsylvania, and Wei Wang, professor of materials science and engineering at Harbin Institute of Technology, are credited as senior authors of a paper detailing the development of these micromotors. The study was published on Oct. 25 in Science Advances.

Researchers tested the technology by moving HeLa cells the oldest and most commonly used cell line for scientific research and silica particles in aqueous media with micromotors. They accomplished this task without damaging nearby particles and cells. In one test, the researchers were able to create letters by pushing particles with the micromotors. In another, they exerted control over the micromotors, making them climb up microscopic blocks and stairs. This test demonstrated that they were capable of navigating over three-dimensional objects.

The micromotors are essentially gold-coated hollow polymer structures that are shaped like a half capsule. Within the body of the micromotor is a tiny magnetic nickel nanoparticle, allowing them to be steered with magnets. The inside surface is treated so it can repel water, so when the micromotor is submerged in water, an air bubble is trapped inside the device. This trapped bubble is integral to the functioning of the micromotor, as it allows the micromotor to respond to ultrasound. Upon receiving ultrasound waves, the trapped bubble begins to oscillate, forming forces that give it an initial push to movement. By applying an external magnetic field, it can move continuously, while altering the direction of the field allows researchers to control the speed and trajectory of the micromotors.

We have a lot of control over the motion, unlike a chemically fueled micromotor that relies on random motion to reach its target, said Fernando Soto, a nanoengineering Ph.D. student studying at UC San Diego. Also, ultrasound and magnets are biocompatible, making this micromotor system attractive for use in biological applications.

The authors plan on making improvements to the micromotors in the coming years. For example, they want to make them more biocompatible using biodegradable polymers and a magnetic material that is less toxic, such as iron oxide. Thanks to this technology, the researchers have opened new possibilities for nanomedicine, tissue engineering, targeted drug delivery, regenerative medicine, and other applications in the field of biochemistry.

See the original post here:
Micromotors move single cells using magnets and ultrasound - CMU The Tartan Online

The Healthcare Nanotechnology Market report delivers a comprehensive overview of the crucial elements of the market and elements such as drivers, current trends of the past and present times, supervisory scenario & technological growth. The report provides useful insights into a wide range of business aspects such as pillars, features, sales strategies, planning models, in order to be enable readers to gauge market scope more proficiently.

Healthcare Nanotechnology Report is based on exploratory techniques like qualitative and quantitative analysis to uncover and present data on the target market. Efficient sales strategies have been mentioned that would business and multiply customers in record time.

The major manufacturers covered in this report:

Amgen

Teva Pharmaceuticals

Abbott

UCB

Roche

Celgene

Sanofi

Merck & Co

Biogen

Stryker

Gilead Sciences

Pfizer

3M Company

Johnson & Johnson

Smith & Nephew

Leadiant Biosciences

Kyowa Hakko Kirin

Shire

Ipsen

Endo International

Sample/Inquire at:

https://www.marketinsightsreports.com/reports/01161054970/global-healthcare-nanotechnology-market-size-status-and-forecast-2019-2025/inquiry?source=MW&mode=82

Healthcare Nanotechnology Market Product Type:

Nanomedicine

Nano Medical Devices

Nano Diagnosis

Other

Healthcare Nanotechnology Market Applications:

Anticancer

CNS Product

Anti-infective

Other

Healthcare Nanotechnology Market Report has been studied and presents an actionable idea to key contributors working in it. The report integrates several drivers as well as factors that impede the growth of this market during the forecast to 2019-2025. An extensive qualitative analysis of factors responsible for driving the market growth and future opportunities has been provided in the market overview section.

Avail Upto 20% Discount On This Report At:

https://www.marketinsightsreports.com/reports/01161054970/global-healthcare-nanotechnology-market-size-status-and-forecast-2019-2025/discount?source=MW&mode=82

This report covers regional analysis including several regions such as North America, Europe, Asia Pacific, Middle East & Africa and Latin America. It focuses on the leading and the progressing countries from every region in detail. South East Asia, Japan, China, and India are also predictable to witness vigorous growth in their respective markets for Global Healthcare Nanotechnology Market in the near future, states the research report.

Important Features that are under Offering and Key Highlights of the Reports:

Detailed overview of Healthcare Nanotechnology Market Changing market dynamics of the industry In-depth market segmentation by Type, Application etc. Historical, current and projected market size in terms of volume and value Recent industry trends and developments Competitive landscape of Healthcare Nanotechnology Market Strategies of key players and product offerings Potential and niche segments/regions exhibiting promising growth

Browse Full Report at:

https://www.marketinsightsreports.com/reports/01161054970/global-healthcare-nanotechnology-market-size-status-and-forecast-2019-2025?source=MW&mode=82

A thorough study of the competitive landscape of the Global Healthcare Nanotechnology Market has been given, presenting insights into the company profiles, financial status, recent developments, mergers and acquisitions, and the SWOT analysis. This research report will give a clear idea to readers about the overall market scenario to further decide on this market project.

We also offer customization on reports based on specific client requirement:

1- Country level analysis for any 5 countries of your choice.

2- Competitive analysis of any 5 key market players.

3- 40 analyst hours to cover any other data points

Contact Us:

Irfan Tamboli (Head of Sales) Market Insights ReportsPhone: + 1704 266 3234 | +91-750-707-8687sales@marketinsightsreports.com | irfan@marketinsightsreports.com

Link:
Healthcare Nanotechnology Market Needs and Demand Analysis 2019 to 2025 - The Chicago Sentinel

Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer. Some of the recent clinical efforts are being targeted at the molecular level characterization of triple-negative breast cancer across emerging therapeutic targets such as epigenetic proteins, PARP1, androgen receptors, receptor and non-receptor tyrosine kinases, and immune checkpoints. These initiatives are anticipated to boost revenue growth of the triple-negative breast cancer treatment market. In a new research study, Persistence Market Research estimates the globaltriple-negative breast cancer treatment marketrevenue to cross US$ 720 Mn by 2026 from an estimated valuation of just under US$ 505 Mn in 2018. This is indicative of a CAGR of 4.7% during the period 2018 to 2026.

Development of generics is another key opportunity area in the triple-negative breast cancer treatment market. With the rapidly expanding number of cancer cases across the world, there is a need for effective cancer management, including the provision of better and more efficient drugs. Developing economies are faced with challenges on several fronts including paucity of funds and lack of proper treatment options, calling for more innovative approaches to affordable healthcare. The availability of biosimilars and affordable generic anti-cancer drugs in developing regions is expected to significantly reduce the burden of cancer care. A projected cost reduction to the tune of more than 30% 40% and extended use of generic drugs is expected to reduce overall cancer treatment costs, thereby increasing the treatment rate for triple-negative breast cancer. This is further anticipated to create lucrative growth opportunities in the global triple-negative breast cancer treatment market.

Advances in Cancer Treatment and Introduction of Innovative Cancer Treatment Drugs to Boost Revenue Growth of the Triple-Negative Breast Cancer Treatment Market

Breast cancer is one of the most common types of cancer in women, and over the years, pharmaceutical and life sciences companies have been conducting advanced research and development activities to devise newer treatment options and drugs to treat breast cancer. Several new drug formulations are currently in the pipeline in different stages of clinical development and this is expected to bode well for the triple-negative breast cancer treatment market. Innovation in oncology therapeutics has shifted focus towards an outcome based approach to cancer care, with an increasing emphasis on combination drugs and newer therapeutic modalities. This is further likely to put the global triple-negative breast cancer treatment market on a positive growth trajectory in the coming years.

Combination Therapy and Advancements in Nano Medicine Research Trending the Triple-Negative Breast Cancer Treatment Market

One of the biggest trends being observed in the global market for triple-negative breast cancer treatment is the shift towards combination therapy. Companies in the global triple-negative breast cancer treatment market are conducting clinical trials for combination therapies by collaborating with other players in the market. Combination therapies are the latest innovation in the field of oncology and the combination of therapeutic drugs with chemotherapy is said to be an effective protocol for the treatment of triple-negative breast cancer.

Another huge trend in the triple-negative breast cancer treatment market is the emergence of nanotechnology as an efficient tool in the clinical management of critical diseases such as triple-negative breast cancer. It has been observed that the combination of gold nanoparticles and folic acid results in higher cell entry rate in both in-vitro and in-vivo models, indicative of the fact that folate receptors are effective targeted therapies for the treatment of triple-negative breast cancer. Nanoparticles facilitate systematic and efficient delivery of drugs and agents to the site of the tumor. Advanced R&D in nanotechnology and nano medicine is one of the top trends likely to impact the global triple-negative breast cancer treatment market in the years to come.

Go here to see the original:
Triple Negative Breast Cancer Treatment Market Rapid Industrialization To Boost Growth By 2018 to 2026 - Zebvo

5 November 2019

Singapore A*STARs Institute of Bioengineering and Nanotechnology (IBN) has teamed up with the Singapore Institute of Advanced Medicine Holdings Pte Ltd (SIAMH) to explore how to better tackle nasopharyngeal carcinoma (NPC), a type of head and neck cancer, through targeted proton therapy.

The two parties are collaborating through an agreement to evaluate and optimise proton therapy for NPC with the use of patient-derived xenografts as well as in vitro 3D organoid models developed at A*STARs IBN, specifically for the treatment of recurrent and radioresistant NPC. The parties will also perform research on designing and establishing novel nano-radiotheranostic agents.

NPC that is detected early is often treated by radiotherapy, concurrently with chemotherapy. However, NPC presents a unique treatment challenge for radiation oncologists due to the proximity of cancer tissues to several critical organs and tissues such as the brain, the spinal cord, the salivary gland, and the optical nerves. Any damage to these adjacent structures could severely impair the quality of life of patients following the treatment.

Figure-1---The-treatment-room-of-a-proton-facility - Image-Credit-SIAMH

Proton therapy could help solve some of these existing treatment challenges. It is a newer mode of radiation therapy that allows proton beams to more precisely irradiate the tumour compared to the x-rays used in conventional radiotherapy. This results in sparing damage to nearby healthy tissues and organs, and potentially less treatment-related side effects for patients to enjoy improved quality of life.

We are excited to partner with SIAMH to explore ways of optimising proton therapy for treating NPC, through leveraging IBNs expertise in developing tumour models and organoids for disease modelling and therapeutic optimisation, said Dr. Lucky Sasidharan, Postdoctoral Fellow at A*STARs IBN.

This collaboration offers a great opportunity to mutually apply our technologies and expertise in an innovative fashion for the benefit of cancer patients, added Dr. Lim Chwee Ming, Adjunct Clinician Scientist at A*STARs IBN.

Figure-2---Components-of-the-proton-facility-of-SIAMH - Image-Credit-SIAMH

Dr. Djeng Shih Kien, Chairman and CEO of SIAMH said, We are very happy to be able to collaborate with A*STAR's IBN and develop a focus group interested in treating Asian cancers like NPC. Although NPC is rare in the Western world, it is common in Asia. There are 300 new cases a year in Singapore alone. It is the 3rd most common cancer in Malaysia, after colorectal and lung cancer.

Dr. Djeng added: Singapore is a small country with limited resources and talent pool. SIAMH's first collaboration with IBN is our attempt to bring together leaders of IBN and the private sector in Singapore as well as domestic and international experts to maximise talent usage. Proton Therapy will be available in Singapore by early 2020. It would significantly reduce side effects due to its characteristic tumour targeting abilities which would be very advantageous in sparing critical structures in the case of NPC patients.

Recently, the group also presented their work at the Australia and New Zealand Head and Neck Cancer Societys Annual Scientific Meeting held at Adelaide[1][1].

NPC is the 9th most common cancer and 7th most frequent cause of cancer related deaths amongst males in Singapore.2 It is often associated with an Epstein-Barr virus (EBV) infection of the white blood cells and nasal lining at the back of the nose. One of the most common signs of newly-diagnosed NPC is the appearance of one or more lumps in the nose or on the neck.

About the Institute of Bioengineering and Nanotechnology

The Institute of Bioengineering and Nanotechnology (IBN) is the worlds first bioengineering and nanotechnology research institute. Established in 2003, IBNs mission is to conduct multidisciplinary research across science, engineering, and medicine for breakthroughs to improve healthcare and quality of life. IBNs research activities are focused on Nanomedicine and Biomaterials, Synthetic Xenobiology and Biosystems, Tissue and Organoid Models, and Green and Safe Biomaterials. The Institute has published over 1,320 papers in leading scientific journals, filed over 660 active patents and patent applications on its inventions, and established 12 spin-off companies. For more information on IBN, please visit http://www.a-star.edu.sg/ibn.

About the Agency for Science, Technology and Research (A*STAR)

The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector agency that spearheads economic oriented research to advance scientific discovery and develop innovative technology. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit society.

As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by contributing to societal benefits such as improving outcomes in healthcare, urban living, and sustainability.

We play a key role in nurturing and developing a diversity of talent and leaders in our Agency and research entities, the wider research community and industry. A*STARs R&D activities span biomedical sciences and physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit http://www.a-star.edu.sg.

About the Singapore Institute of Advanced Medicine Holdings Pte Ltd

The Proton Therapy Pte Ltd, a subsidiary of the Singapore Institute of Advanced Medicine Holdings Pte Ltd (SIAMH), will provide proton beam therapy treatment in Singapore. It is part of a new oncology center that is located at the Biopolis, Singapore. The new oncology center will include a comprehensive diagnostic center providing both imaging and laboratory services using advance medical technologies. Its training facility, the Advanced Medicine Training Centre, will provide the necessary training to the specialists in this part of the world. For more information, search proton.sg.

See more here:
Taking Better Aim at Nasopharyngeal Carcinoma Using Proton Therapy - BioSpace

Over billions of years nature has perfected ingenious ways for biological cells to move around their environment and harmlessly transport packages of chemicals between one another.

Now scientists are mimicking some of these processes to create new nanomachines that could eventually help treat diseases like leukaemia and other cancers.

One approach takes its inspiration from the story of the siege of Troy, when the Greeks hid their warriors inside a giant wooden horse in order to get inside the city.

Professor Valentina Cauda, a chemical engineer at the Politecnico di Torino in Italy, is leading a project to create nano-sized crystals of zinc oxide that can kill cancer cells from the inside. By themselves the crystals, which are around 20 nanometres in size about 6,000 times smaller than the width of a human hair can be toxic to healthy cells in the body and can trigger an immune reaction that prevents them from reaching the tumour.

But Prof. Cauda and her colleagues on the TrojaNanoHorse project have developed a shell around the crystals so they can slip them past the bodys defences and inside cancer cells.

The idea is to elude the immune system and to elude the barrier of the cell membrane thanks to the biomimetic shell, says Prof. Cauda. In the Trojan horse analogy, the (cancer) cell can be the city of Troy.

Fatty

The tiny shells, which are between 100-200nm or 1,000 times smaller than a human hair, are made from fatty molecules called lipids that form the outer membrane of almost all living cells. In nature, small droplets made from these lipids known as vesicles constantly bud off from the surface of our cells with chemical messages or unwanted materials inside so they can be carried safely to other parts of the body.

Prof. Cauda and her team have tried to copy this by coating their nanocrystals in vesicles produced by cells grown in the lab so they too can pass harmlessly through the body. The surface of the vesicles can also be studded with antibodies against specific cancer cells, helping them to hone in on only the cells they want to kill.

Once a vesicle finds a cancer cell, its antibodies will bind to the surface, allowing the lipids to merge with the cell and releasing the toxic nanocrystal inside. And by growing nanoshells from cells taken from a patients own body, Prof. Cauda believes it will be possible to create personalised treatments that can evade the immune system while still killing cancer cells.

The team have already tested the nanoshell approach against leukaemia cells and cervical cancer in the laboratory. While they hope to be able to perform human trials in the future, Prof. Cauda warned it could still be many years before they reach that stage.

Benefits

If successful, however, this nanomedicine approach could bring benefits compared to traditional chemotherapy treatments by only targeting tumour cells, leaving healthy tissue unaffected and so reducing side-effects.

The nanomedicine approach could offer a site-selective and personalised treatment for the patient, said Prof. Cauda.

In the Trojan horse analogy, the (cancer) cell can be the city of Troy.

Professor Valentina Cauda, Politecnico di Torino, Italy

This approach, however, still largely relies upon the nanoshells chancing upon the cancer cells as they circulate in the patients bloodstream so they can attach to them.

Another team of researchers are working on nano- and micro-machines that might actively be able to improve this by carrying treatments to the site in the body where they are needed.

Dr Larisa Florea, a materials scientist at Trinity College Dublin in Ireland, is leading a project called ChemLife to create miniature vehicles that can move by themselves in a liquid.

Chemotaxis

The team is attempting to emulate a form of movement known as chemotaxis, which is employed by some basic microorganisms and enables them to move through solutions from low salinity to high salinity, or from acidic to alkaline solutions, for example.

Other research teams in the US have previously shown that man-made droplets can be very precisely navigated through complex mazes with this approach. Dr Florea and her colleagues have sought to extend this by using light to control the movement of droplets.

They have created vesicle-like droplets that pair light sensitive molecules with compounds known as surfactants. Surfactants are commonly found in detergents but are also commonly found in many biological systems.

When exposed to light, the photosensitive molecules react by changing their shape, altering the surface tension on each side of the droplet. This causes the molecules in the droplet to flow from one side to the other, driving it forward, a little like the tread of a tank.

The team have shown they can accurately steer droplets through three dimensional spaces and reach speeds of up to 10.4mm per second (0.02mph).

By adding a photoactive material to a droplet, scientists have been able to control its movement in three dimensions through water using light. Video credit -Yang Xiao (author) and co-authors: Sara Zarghami, Klaudia Wagner, Pawel Wagner, Keith C. Gordon, Larisa Florea, Dermot Diamond, David L. Officer.

If you compare the speed of the movement to the size of these microdroplets, they are faster, pound for pound, than some of the best swimmers in the world, said Dr Florea.

They have also been able to demonstrate that their droplet-shaped vehicles can carry cargo, delivering it to other droplets to trigger a chemical reaction. It raises hopes that similar methods could be used to deliver drugs or other sorts of treatments to specific cells in the body.

While it may be difficult to use light to navigate a drug-carrying droplet through the body, Dr Florea and her colleagues have also explored using mild electrical currents.

Propel

The team have also been developing more complex micromachines that can swim or crawl through liquids like tiny bacteria. Using highly precise 3D printing techniques, they have been able to create hydrogel structures around a few micrometres in size that can contract and expand to propel a structure forward.

We have been making tiny flower-like structures, for example, that can open and close in response to different stimuli, she said. For example it might open at a certain pH and close at another.

This happens because the hydrogels expand by absorbing water and contract by expelling it according to the pH of the surrounding solution.Dr Florea said they hope to also control the movement of hydrogels with changes in temperature or pulses of light.

The ChemLife team are using these hydrogels to create structures with tiny rotating flagella the tiny tail-like appendages that some bacteria use to propel themselves. They are also creating worm-like structures from the same kind of hydrogels that can crawl along surfaces or through liquids.

The ultimate goal is to have these micro-vehicles perform actions like drug delivery or (chemical) sensing, said Dr Florea. But we have to be realistic that this might not be achieved in the near future as the body is a very difficult environment.

The tiny moving structures could also find uses in other ways too. These include delivering chemicals to better improve industrial reactions or creating soft micro-grippers that could be remotely activated to handle delicate components like cells without damaging them.

When you look at what nature can achieve, the opportunities are endless, added Dr Florea.

The research in this article was funded by the EUs European Research Council. If you liked this article, please consider sharing it on social media.

See the rest here:
Nanovehicles that mimic nature could deliver treatments of the future - Horizon magazine

Nanomedicine Market report has been structured after a thorough study of various key market segments like market size, latest trends, market threats and key drivers which drives the market. This market study report has been prepared with the use of in-depth qualitative analysis of the global market. The report displays a fresh market research study that explores several significant facets related to Nanomedicine Market covering industry environment, segmentation analysis, and competitive landscape. This global market research report is a proven source to gain valuable market insights and take better decisions about the important business strategies.

Industry Analysis:

Global nanomedicine market is registering a healthy CAGR of 15.50% in the forecast period of 2019-2026. This rise in the market value can be attributed to increasing number of applications and wide acceptance of the product globally. There is a significant rise in the number of researches done in this field which accelerate growth of nanomedicine market globally.

Top Dominating Competitors are: Abbott, Invitae Corporation, General Electric Company, Leadiant Biosciences, Inc., Johnson & Johnson Services, Inc., Mallinckrodt, Merck Sharp & Dohme Corp., NanoSphere Health Sciences, Inc., Pfizer Inc., CELGENE CORPORATION, Teva Pharmaceutical Industries Ltd., Gilead Sciences, Inc., Amgen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Luminex Corporation, Eli Lilly and Company, Nanobiotix, Sanofi, UCB S.A., Ablynx among others.

Nanomedicine Market Report incorporates the precisely contemplated and surveyed information related to the Nanomedicine Market by utilizing various explanatory tools and techniques. The explanatory devices, for example, PEST analysis, Porters five Forces examination, SWOT investigation, speculation return examination and feasibility analysis have been utilized to break down complex Nanomedicine Market data.

Market Drivers and Restraint:

Table of Contents:

Chapter 1 Industry Overview:

Chapter 2 Premium Insights

Chapter 3 Production Market Analysis:

Chapter 4 Major Market Classification:

Chapter 5 Major Application Analysis:

Chapter 6 Industry Chain Analysis:

Chapter 7 Major Manufacturers Analysis:

Chapter 8 New Project Investment Feasibility Analysis:

Chapter 9 Market Driving Factors:

Explore Full Report with Detailed TOC Here at https://www.databridgemarketresearch.com/toc/?dbmr=global-nanomedicine-market

Geographical landscape

Have look on the Premium Insights of the Report

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: Corporatesales@databridgemarketresearch.com

More here:
Nanomedicine Market Analysis by Growth, Segmentation, Performance, Competitive Strategies with Top Players Pfizer Inc., CELGENE CORPORATION, Teva...

Japanese researchers have developed a machine learning model that allows scientists to reconstruct the neuronal circuitry of the brain by measuring signals from the neurons themselves.

According to experts in the field, the brain is considered to be one of the most complex systems in existence. While significant headway has been made to understand how the brain works, researchers tend to generate more questions than answers about this entity.

However, the creators of the machine learning model - a team from Kyoto University - believe it has the potential to explain the difference in neuronal computation in different brain regions more clearly.

To comprehend the brain, neurologists must look at the neurons that construct it. Our entire world of perception runs across these billions of cells in our head and that is compounded by the exponentially larger number of connections known as synapses between them. This, therefore, makes the path to our understanding of the brain a challenge.

Shigeru Shinomoto from Kyoto Universitys School of Science, who led the project, explained that although it is possible to record the activity of individual neurons in the brain and that number has increased dramatically over the last decade it is still a challenge to map out how each of these cells connects to each other.

It has been suggested that neuronal connectivity can be estimated by analysing the correlation between neuronal signals, Shinomoto explained. But getting accurate inference was difficult because of the amount of external noise coming from other neurons.

As part of their study, the team constructed an analytical method that takes the signal spikes from individual neurons and estimates the inter-neuronal connections from them.

To eliminate data-contaminating 'noise', the researchers applied a generalised linear model (GLM), a basic model in machine learning, to a cross correlogram (an image of correlation statistics) that records the firing correlation between neurons.

We called our analysis GLMCC and it estimated the strength of nerve connections in units of synaptic membrane potential, said Ryota Kobayashi from the National Institute of Informatics (NII) based in Tokyo.

To confirm if our data reflected real-world connectivity, we evaluated its accuracy through a simulation of a large network of neurons. We confirmed that the new model has an accuracy of 97 per cent, much higher than any previous method.

A brain circuit diagram can be obtained by applying the GLMCC (Generalised Linear Model for Cross Correlation) programme

Image credit: Kyoto University/Shinomoto Lab

The model was then applied to experimental data of neuron activity in the hippocampus (a brain structure embedded deep in the temporal lobe of each cerebral cortex) of rats. When analysed, the team found the estimated connections matched the results inferred with other physiological cues.

A 'ready-to-use' version of the deep learning model is available online and the team hopes it will be utilised by neuroscientists around the world.

Shinomoto concluded: As we advance in technology, the amount of neurological data we collect will increase. Our new analytical model will be vital in processing that information and will lead us to better understand how our brains process the world around us.

The paper, Reconstructing Neuronal Circuitry from Parallel Spike Trains,waspublished in the journalNature Communications.

In April, researchers from UC Berkeley and the US Institute for Molecular Manufacturing (iMM) predicted that exponential progress in nanotechnology, nanomedicine, artificial intelligence and computation will lead to the development of a human brain/cloud interface and will give people instant access to vast knowledge and computing power via thought alone.

In October 2018, E&Texplored advances in neuroimaging which could pave way for researchers to observe brain activity in real-time, investigating how these new techniques could reshape the way mental illness is diagnosed and treated.

Sign up to the E&T News e-mail to get great stories like this delivered to your inbox every day.

Read more from the original source:
Machine learning constructs map of the brain's neural circuit - E&T Magazine

Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer. Some of the recent clinical efforts are being targeted at the molecular level characterization of triple-negative breast cancer across emerging therapeutic targets such as epigenetic proteins, PARP1, androgen receptors, receptor and non-receptor tyrosine kinases, and immune checkpoints. These initiatives are anticipated to boost revenue growth of the triple-negative breast cancer treatment market. In a new research study, Persistence Market Research estimates the globaltriple-negative breast cancer treatment marketrevenue to cross US$ 720 Mn by 2026 from an estimated valuation of just under US$ 505 Mn in 2018. This is indicative of a CAGR of 4.7% during the period 2018 to 2026.

Development of generics is another key opportunity area in the triple-negative breast cancer treatment market. With the rapidly expanding number of cancer cases across the world, there is a need for effective cancer management, including the provision of better and more efficient drugs. Developing economies are faced with challenges on several fronts including paucity of funds and lack of proper treatment options, calling for more innovative approaches to affordable healthcare. The availability of biosimilars and affordable generic anti-cancer drugs in developing regions is expected to significantly reduce the burden of cancer care. A projected cost reduction to the tune of more than 30% 40% and extended use of generic drugs is expected to reduce overall cancer treatment costs, thereby increasing the treatment rate for triple-negative breast cancer. This is further anticipated to create lucrative growth opportunities in the global triple-negative breast cancer treatment market.

Advances in Cancer Treatment and Introduction of Innovative Cancer Treatment Drugs to Boost Revenue Growth of the Triple-Negative Breast Cancer Treatment Market

Breast cancer is one of the most common types of cancer in women, and over the years, pharmaceutical and life sciences companies have been conducting advanced research and development activities to devise newer treatment options and drugs to treat breast cancer. Several new drug formulations are currently in the pipeline in different stages of clinical development and this is expected to bode well for the triple-negative breast cancer treatment market. Innovation in oncology therapeutics has shifted focus towards an outcome based approach to cancer care, with an increasing emphasis on combination drugs and newer therapeutic modalities. This is further likely to put the global triple-negative breast cancer treatment market on a positive growth trajectory in the coming years.

Combination Therapy and Advancements in Nano Medicine Research Trending the Triple-Negative Breast Cancer Treatment Market

One of the biggest trends being observed in the global market for triple-negative breast cancer treatment is the shift towards combination therapy. Companies in the global triple-negative breast cancer treatment market are conducting clinical trials for combination therapies by collaborating with other players in the market. Combination therapies are the latest innovation in the field of oncology and the combination of therapeutic drugs with chemotherapy is said to be an effective protocol for the treatment of triple-negative breast cancer.

Another huge trend in the triple-negative breast cancer treatment market is the emergence of nanotechnology as an efficient tool in the clinical management of critical diseases such as triple-negative breast cancer. It has been observed that the combination of gold nanoparticles and folic acid results in higher cell entry rate in both in-vitro and in-vivo models, indicative of the fact that folate receptors are effective targeted therapies for the treatment of triple-negative breast cancer. Nanoparticles facilitate systematic and efficient delivery of drugs and agents to the site of the tumor. Advanced R&D in nanotechnology and nano medicine is one of the top trends likely to impact the global triple-negative breast cancer treatment market in the years to come.

Read the rest here:
Triple Negative Breast Cancer Treatment Market is Countable to Translate to a Revenue of CAGR 4.7% by 2018 to 2026 in Step With Market Forecast -...

Medical technologies like smart pills, vaccines personalization, and more are opening newer ways for cancer treatment.

FREMONT, CA: Treatment options for cancer have massively evolved and improved in recent years. Today, care providers continue to explore new possibilities for cancer treatment with the help of advanced technologies. Treatments like radiation therapy, personalization of cancer vaccines, and nano-medicines, experience rapid adoptions by care providers for cancer treatment.

1. Radiation Therapy

Health care providers use radiation therapy, highly effective cancer treatment. This treatment aims accurately and directly at the cancer cells, resulting in the killing or reduction of the tumor-affected cells and tissues in the patients. The high-energy rays prove to be highly effective in reducing the risk of cancer and recurrence of common cancer, such as breast cancer, bowel cancer, and prostate cancer, and helps the surgeons remove or kill the cancer-affected tissues. The latest medical technologies for cancer integrated with radiation therapy are making the treatments more quick, accurate, and effective.

2. Ingestible Sensors and Smart Pills

Ingestible technology in the healthcare field is used to help the patients manage their medications. The new technology allows the care providers to ensure their cancer patients are taking medications as prescribed. Ingestible sensors offer close monitoring of patients' health conditions, which include sensing the growth of tumors and instantly guiding the smart pills towards precise tumor locations and heart rate, activity level, and sleep cycle of the patients. The digital pills enable real-time transmission of health information to a small patch on the patients' skin, which can be connected to a mobile app that both the patients and their doctors can access.

3. Personalized Cancer Vaccines

Developments in personalized cancer vaccines enable the next-generation cancer treatment method. The advanced vaccine is used with the computational pipeline, which can precisely identify tumor-unique mutations and successfully induce immune responses in cancer patients, helping them fight their diseases. The technique follows cell-based immune therapies that provide the patients with tumor-attacking T cells, and the delivered neo-antigens in the patients body create vaccines to stimulate the T cells. The advanced vaccines are given in the form of messenger RNA that produces a particular protein according to the patients physiological requirements.

4. Nano-Medicines

The innovative and promising technology, nano-medicine provides many advantages over conventional cancer therapies and new opportunities for early detection, improved treatment, and diagnosis of cancer. The benefits of nano-medicines for cancer treatment attract care providers, as the unique physical, chemical, mechanical, and optical properties of these medicines are easier to access with more efficiency. The innovative medicine uses nano-carriers to deliver therapeutic molecules, such as drugs, proteins, or nucleic acids. The nano-structures for the cancer treatment can also be exploited to favor the delivery of immune agents and represent therapeutic tool.

Technology leads the cancer treatment sector towards a bright future, where the increasing advantages of innovative cancer treatment solutions can be accessed easily across the world. Nanotechnology, targeted radiation, personalized vaccines are revolutionizing the medical technology industry, promising the possibilities of more solutions that can successfully fight cancer and prevent its reoccurrence. The ever-evolving field of cancer treatments consistently puts effort into exploring innovative diagnostics and treatments, leading to more creative solutions like molecular cancer diagnostics, identify genetic and lifestyle causes of diseases, and perform precision surgery.

Link:
4 Innovative Solutions Fostering Advanced Cancer Treatment - Medical Tech Outlook

PITTSBURGH, Oct. 23, 2019 /PRNewswire/ -- While major drug companies reached a $260 million settlement to avert a federal opioid trial this week, the crisis continues to impact Americans. Researchers at Duquesne University think they have some answers.

Here's How We Can End the Opioid Crisiswill feature brief presentations from members of Duquesne's Chronic Pain Research Consortium, including:

The 45-minute session will begin at 9:30 a.m. on Thursday, October 24. To view the presentation live, click here.

The session is part of Duquesne's Integrative Health Summit, which highlights the university's growing momentum in health sciences education and research. Other sessions will focus on new treatments for deadly diseases; children and family health issues, including the anti-vaccine movement; how integrative techniques help serve marginalized populations, including sexual assault victims and those dealing with violence-related trauma; and the role of the arts in medicine.

Earlier this year, Duquesne announced that it's creating a College of Osteopathic Medicine to help meet a looming physician shortage in the U.S.

Duquesne UniversityFounded in 1878, Duquesne is consistently ranked among the nation's top Catholic universities for its award-winning faculty and tradition of academic excellence. Duquesne, a campus of nearly 9,500 graduate and undergraduate students, has been nationally recognized for its academic programs, community service and commitment to sustainability. Follow Duquesne University on Facebook, Twitter and Instagram.www.duq.edu

Excerpt from:
Researchers Explore How to End the Opioid Crisis at Web Event Tomorrow - Bradford Era

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 21, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, recently presented data at the American Society of Anesthesiologists (ASA) ANESTHESIOLOGY annual meeting from a Phase I/II clinical trial which showed TLC590 to yield more immediate and long-lasting pain reduction than ropivacaine. In addition, in vivo findings in which TLC590 showed no dose-related toxicity and other preclinical data were recently published in the International Journal of Nanomedicine. TLC590 is a non-opioid, BioSeizer formulation of ropivacaine with the aim to manage postsurgical pain for four to seven days with a single dose, potentially deterring the use of opioids following surgery.

At ANESTHESIOLOGY 2019, which took place October 19-23 at the Orange County Convention Center in Orlando, FL, principal investigator Todd Bertoch, MD, Chief Medical Officer at JBR Clinical Research, a CenExel Clinical Research Center of Excellence, presented findings from a Phase I/II, randomized, double-blind, comparator-controlled, dose-escalation study of TLC590 following inguinal hernia repair.

Highlights from the e-poster presentation are as follows:

I am delighted to have had the opportunity to present these fantastic results, said Dr. Todd Bertoch. As a clinical researcher specializing in pain, it is so rewarding to be able to share findings that provide hope for a real, substantive weapon in the war against opioids. Clinicians have been waiting patiently for safe, easily administered, very long acting local anesthetics with a rapid onset. These data suggest that we may have found one.

Results of studies evaluating the release profile of TLC590 in vitro and its pharmacokinetics and anesthetic effect in vivo were recently published in the International Journal of Nanomedicine.

Highlights from the publication article are as follows:

The poster presentation and full text article can be accessed under Publications in the Pressroom section of TLCs website at http://www.tlcbio.com.

About TLC590

TLC590 is a non-opioid, BioSeizer sustained release formulation of ropivacaine designed to prolong the retention time of ropivacaine around the injection site as a drug depot, simultaneously extending its therapeutic period and reducing unwanted systemic exposure. A Phase II, randomized, double-blind, comparator- and placebo-controlled clinical trial to evaluate the safety, pharmacokinetics and efficacy of TLC590 following bunionectomy is ongoing.

About TLC

TLC (NASDAQ: TLC, TWO: 4152) is a clinical-stage specialty pharmaceutical company dedicated to the research and development of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD). TLC believes that its deep experience with liposome science allows a combination of onset speed and benefit duration, improving active drug concentrations while decreasing unwanted systemic exposures. TLCs BioSeizer technology is designed to enable local sustained release of therapeutic agents at the site of disease or injury; its NanoX active drug loading technology is designed to alter the systemic exposure of a drug, potentially reducing dosing frequency and enhancing distribution of liposome-encapsulated active agents to the desired site. These technologies are versatile in the choice of active pharmaceutical ingredients, and scalable with respect to manufacturing. TLC has a diverse, wholly owned portfolio of therapeutics that target areas of unmet medical need in pain management, ophthalmology, and oncology.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include, without limitation, statements regarding TLCs expectations regarding the clinical development of TLC590, the clinical benefits of TLC590 for postsurgical pain management, the timing, scope, progress and outcome of the clinical trials, and the anticipated timelines for the release of clinical data. Words such as may, believe, will, expect, plan, anticipate, estimate, intend and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance and involve a number of risks, assumptions, uncertainties and factors, including risks that the outcome of any clinical trial is inherently uncertain and TLC590 or any of our other product candidates may prove to be unsafe or ineffective, or may not achieve commercial approval. Other risks are described in the Risk Factors section of TLCs annual report on Form 20-F for the year ended December 31, 2018 filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on TLCs expectations and assumptions as of the date of this press release. Actual results may differ materially from these forward-looking statements. Except as required by law, TLC expressly disclaims any responsibility to update any forward-looking statement contained herein, whether as a result of new information, future events or otherwise.

Read more:
TLC Presents Clinical and Preclinical Data of TLC590 at ANESTHESIOLOGY Annual Meeting and in International Journal of Nanomedicine TLC590 showed...

Rizia Bardhan

With a research specialty in nanomedicine and nanophotonics and designing materials that fight diseases using image-guided techniques Rizia Bardhan will join the faculty of the Department of Chemical and Biological Engineering in January, 2020.

Bardhan, who has been hired as a tenured associate professor, comes to Iowa State from Vanderbilt University, where she has been an assistant professor in the Department of Chemical and Biomolecular Engineering since 2012.

Her research focuses on designing nanomaterials that can be activated by external stimuli and then utilize them for biomedical imaging, and image-guided drug delivery and immunotherapies across many disease models, including cancer, neurodegenerative disease and infection. She also develops point of care diagnostics that she is currently applying for early detection of preterm birth in pregnant women. Click here for more on her current research.

Prior to joining the faculty of Vanderbilt University she was a postdoctoral fellow at The Molecular Foundry, Lawrence Berkeley National Laboratory, Berkeley, CA.

She received a B.A. in mathematics and chemistry at Westminster College, Fulton, Missouri, in 2005 and a Ph.D. in chemistry at Rice University in 2010 under the guidance of Prof. Naomi Halas, a pioneer in nanophotonics and plasmonics.

In the 2020 spring semester at Iowa State she will teach ChE 381, chemical engineering thermodynamics.

Outside of research and teaching, Bardhan enjoys spending time outdoors with her two sons Elan (3) and Jonah (5), and husband Cary Pint, who is also a new Iowa State University faculty member, joining the Department of Mechanical Engineering in January.

Read more here:
New CBE professor Bardhan to bring image-guided techniques to fight against disease College of Engineering News Iowa State University - Iowa State...

Nanorobotic is a new technology of robot engineering. The development of nano-robot belongs to molecular nanotechnology

Nanorobotic Marketreport offers a comprehensive valuation of the marketplace. It does so via in-depth comprehensions, grateful market growth by pursuing past developments, and studying the present situation and future forecasts based on progressive and likely areas. Each research report supports as a depository of analysis and data for each and every side of the industry, including but not limited to: Regional markets, types, applications, technology developments and the competitive landscape.

The Nanorobotic Market report profiles the following companies, which includes: Bruker, Jeol, Thermo Fisher Scientific, Ginkgo Bioworks, Oxford Instruments, Ev Group, Imina Technologies, Toronto Nano Instrumentation, Klocke Nanotechnik, Kleindiek Nanotechnik, Xidex, Synthace, Park Systems, Smaract, Nanonics Imaging

Get Sample Copy of this Report at @https://www.reportsintellect.com/sample-request/581106

Report Description:-

This report presents a comprehensive overview, market shares and growth opportunities of Nanorobotic market by product type, application, key companies and key regions.

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Product Type Coverage:-Nanomanipulator, Bio-Nanorobotic, Magnetically Guided Robot

Product Application Coverage:-Nanometer Medicine, Biomedical, Machine, Other

Market Segment by Regions, regional analysis coversNorth America (United States, Canada and Mexico)Europe (Germany, France, UK, Russia and Italy)Asia-Pacific (China, Japan, Korea, India and Southeast Asia)South America (Brazil, Argentina, Colombia etc.)Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Get 10% Discount on ThisReport@https://www.reportsintellect.com/discount-request/581106

Table of Content:

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered1.4 Market Analysis by Type1.5 Market by Application1.6 Study Objectives1.7 Years Considered

2 Global Growth Trends2.1 Nanorobotic- Market Size2.2 Nanorobotic- Growth Trends by Regions2.3 Industry Trends

3 Market Share by Key Players3.1 Nanorobotic- Market Size by Manufacturers3.2 Nanorobotic- Key Players Head office and Area Served3.3 Key Players Nanorobotic- Product/Solution/Service3.4 Date of Enter into Nanorobotic- Market3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product4.1 Global Nanorobotic- Sales by Product4.2 Global Nanorobotic- Revenue by Product4.3 Nanorobotic- Price by Product

5 Breakdown Data by End User5.1 Overview5.2 Global Nanorobotic- Breakdown Data by End User

Research objectives

About Us:-Reports Intellect is your one-stop solution for everything related to market research and market intelligence. We understand the importance of market intelligence and its need in todays competitive world.

Our professional team works hard to fetch the most authentic research reports backed with impeccable data figures which guarantee outstanding results every time for you.

So, whether it is the latest report from the researchers or a custom requirement, our team is here to help you in the best possible way.

Contact Us:

Sales@reportsintellect.comPH + 1-706-996-2927US Address:225 Peachtree Street NE,Suite 400,Atlanta, GA 30303

Read the rest here:
Nanorobotic Market 2019 Technological Perspective, Latest Trends and key manufacturers:: Bruker, Jeol, Thermo Fisher Scientific, Ginkgo Bioworks -...

Los Angeles, United States, In a recent study published by QY Research, titled, Nanobots Market Research Report, analysts offers an in-depth analysis of global Nanobots market. The study analyses the various aspect of the market by studying its historic and forecast data. The research report provides Porters five force model, SWOT analysis, and PESTEL analysis of the Nanobots market. The different areas covered in the report are Nanobots market size, drivers and restrains, segment analysis, geographic outlook, major manufacturers in the market, and competitive landscape.

The report provides accurate historic figures and estimates about the future to the readers. The report also mentions the expected CAGR of the global Nanobots market during the forecast period.

Get PDF template of this report: https://www.qyresearch.com/sample-form/form/1148108/global-nanobots-market-report-history-and-forecast-2014-2025-breakdown-data-by-manufacturers-key-regions-types-and-application

Key manufacturers in the Nanobots market:

The report lists some of the key manufacturers operating in the global Nanobots market. Their revenue data, shares in the market, historic and forecast are all covered in this section.

Xidex CorpZymergen IncSynthace LimitedGinkgo BioworksAdvanced Diamond TechnologiesAdvanced Nano Products Co Limited

Segment Analysis of the Nanobots market:

The segment analysis of the Nanobots market includes the major two segments as type and application, and end user. Such a segmentation enables a granular view of the market that is imperative to understand the finer nuances.

Global Nanobots Market by Type Segments:

Microbivore NanorobotsRespirocyte NanorobotsClottocyte NanorobotsCellular Repair Nanorobots

Global Nanobots Market by Application Segments:

Nano MedicineBiomedicalMechanicalOther applications

Geographical Outlook of the Nanobots market:

The geographic outlook of the Nanobots market contains analysis of all the regions which occupy the regional shares of the market. This section provides you with all the information about the revenue generated by different regions from import, export, and manufacturing.

Get Customized Report in your Inbox within 24 hours @ https://www.qyresearch.com/customize-request/form/1148108/global-nanobots-market-report-history-and-forecast-2014-2025-breakdown-data-by-manufacturers-key-regions-types-and-application

Scope of Global Nanobots Market

The research report gives a wide overview of the new and emerging trends in the Nanobots market. The report provides an assessment of the strengths and weaknesses of the market along with the other factors which are expected to hinder the market. It also explains the dynamics of Nanobots market in detail for a comprehensive understanding.

The drivers in the Nanobots market are all the external factors which are expected to contribute towards its growth. It contains the data from different industries which are expected to grow and create more demand and opportunities for the products in the future. This will help reader understand the trajectory of the Nanobots market for making sound investments and better business decisions.

The restraints in the Nanobots market includes all the factors which might hamper its growth in future. Studying the market restraints will help readers understand the challenges the Nanobots market might face. It will also help them take necessary measures to avert loses. In addition, the report also includes a list of opportunities present in the global Nanobots market.

The Nanobots market scope will allow the reader to have all the necessary information of the Nanobots market that might be helpful to the readers.

Competitive Landscape of the Nanobots market:

Competitive landscape studies new strategies being used by different manufacturers for increasing the competition or maintain their position in the Nanobots market. Strategies such as product development, innovative technologies, mergers and acquisitions, and joint ventures are covered in the research report. This will help the reader understand the current trends that are growing at a fast pace. It will also update the reader about the new products which are replacing the traditional once. All this has been explained in complete detail for absolute clarity.

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry.

More:
Nanobots Market Size Trends, Revenue, Regional Segmented Analysis and Outlook 2025 - Update in Seconds